Please wait while the formulary information is being retrieved.
TRELSTAR (triptorelin pamoate)
- Advanced prostatic carcinoma
11.25 mg intramuscular suspension
- Inject 11.25 mg by intramuscular route every 12 weeks as a single dose
22.5 mg intramuscular suspension
- Inject 2 milliliters (22.5 mg) by intramuscular route once every 24 weeks
3.75 mg intramuscular suspension
- Inject 3.75 mg by intramuscular route every 4 weeks
11.25 mg intramuscular suspension
- Inject 11.25 mg by intramuscular route every 12 weeks as a single dose
22.5 mg intramuscular suspension
- Inject 2 milliliters (22.5 mg) by intramuscular route once every 24 weeks
3.75 mg intramuscular suspension
- Inject 3.75 mg by intramuscular route every 4 weeks
Advanced prostatic carcinoma
- Inject 3.75 mg by intramuscular route once a month
- Inject 11.25 mg by intramuscular route every 12 weeks as a single dose
- Inject 3.75 mg by intramuscular route every 4 weeks
- Inject 2 milliliters (22.5 mg) by intramuscular route once every 24 weeks
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
- Pregnancy
Contraindicated
- Chronic heart failure
- Congenital long QT syndrome
- Hypokalemia
- Hypomagnesemia
- Prolonged QT interval
- Spinal cord compression
Severe
Moderate
- Acute myocardial infarction
- Cerebrovascular accident
- Diabetes mellitus
- Disease of liver
- Hypercholesterolemia
- Hypertension
- Increased cardiovascular event risk
- Kidney disease with reduction in GFR
- Obesity
- Tobacco smoker
- Urinary tract obstruction
- Vertebral metastases
TRELSTAR (triptorelin pamoate)
- Advanced prostatic carcinoma
- Hypertension
- Bone pain
- Erectile dysfunction
- Flushing
- Limb pain
- Testicular atrophy
More Frequent
Severe
Less Severe
- Anemia
- Chest pain
- Transient testosterone increase in males
- Urinary retention
- Urinary tract infection
- Abnormal hepatic function tests
- Acute abdominal pain
- Anorexia
- Arthralgias
- Back pain
- Conjunctivitis
- Constipation
- Cough
- Cramps in legs
- Diarrhea
- Dizziness
- Dyspepsia
- Fatigue
- Gynecomastia
- Headache disorder
- Hyperglycemia
- Injection site sequelae
- Insomnia
- Mastalgia
- Mood changes
- Myalgias
- Ocular pain
- Pain
- Peripheral edema
- Pruritus of skin
- Skin rash
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Anaphylaxis
- Angioedema
- Cancer-related spinal cord compression
- Cerebrovascular accident
- Deep venous thrombosis
- Diabetes mellitus
- Hematuria
- Pituitary apoplexy
- Pulmonary thromboembolism
- Seizure disorder
- Thromboembolic disorder
- Transient cerebral ischemia
Less Severe
- Thrombophlebitis
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Triptorelin (Prostate CA)
No safety and efficacy. Indicated for advanced prostate cancer.
- 1 Day – 18 Years
- No safety and efficacy. Indicated for advanced prostate cancer.
Triptorelin
- Severity Level:
1
- Additional Notes: Theoretical risk based on drug mechanism of action and animal data.
Contraindicated
Triptorelin
Insufficient data available; should not be used by nursing mothers per mfr
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insufficient data available; should not be used by nursing mothers per mfr |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Advanced prostatic carcinoma | |
| C61 | Malignant neoplasm of prostate |
| 0-9 | A-Z |
|---|---|
| C61 | Malignant neoplasm of prostate |
Formulary Reference Tool